 The FDA has signed off Monopar Therapeutics Incs NASDAQ: MNPR IND to commence an open-label Phase 1b dose-escalation trial to evaluate camsirubicin plus pegfilgrastim in patients with advanced soft tissue sarcoma ASTS. Enrollment will start in Q4 of 2021. 